[Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon, France: International Agency for Research on Cancer; 2008.]Search in Google Scholar
[Žakelj Primic M, Bračko M, Pompe-Kirn V, Zakotnik B, editors. Rak v Sloveniji 2007. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2010.]Search in Google Scholar
[Shipp M, Harrington D, Anderson J, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkincs lymphomas. N Engl J Med 1993; 329: 987-94.10.1056/NEJM1993093032914028141877]Search in Google Scholar
[Strojan-Flezar M, Lavrencak J, Zganec M, Strojan P. Image cytometric nuclear texture features in inoperable head and neck cancer: a pilot study. Radiol Oncol 2011; 45: 40-50.10.2478/v10019-011-0002-y342372022933933]Search in Google Scholar
[Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-8.10.2478/v10019-010-0007-y342367522933885]Search in Google Scholar
[Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2006; 66: 791-820.10.2165/00003495-200666060-0000516706552]Search in Google Scholar
[Molina A. A decade of rituximab: improving survival outcomes in nonHodgkin's lymphoma. Annu Rev Med 2008; 59: 237-50.10.1146/annurev.med.59.060906.22034518186705]Search in Google Scholar
[Jezeršek Novaković B, Benigar A. Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients. Med Oncol 2010; 27: 167-76.10.1007/s12032-009-9188-x19263255]Search in Google Scholar
[Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373-80.10.1200/JCO.2009.26.249320385988]Search in Google Scholar
[Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.10.1182/blood-2006-08-03825717105812]Search in Google Scholar
[Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): 172-4.10.1093/annonc/mdq20320555073]Search in Google Scholar
[Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999: 17: 1244-53.10.1200/JCO.1999.17.4.124410561185]Search in Google Scholar
[Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 2008; 46: 213-23.10.1016/j.rcl.2008.03.003]Search in Google Scholar
[Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003; 121: 44-8.10.1046/j.1365-2141.2003.04274.x]Search in Google Scholar
[Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.10.1056/NEJMoa011795]Search in Google Scholar
[Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-33.10.1200/JCO.2005.09.137]Search in Google Scholar
[Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.10.1200/JCO.2005.09.131]Search in Google Scholar
[Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-7.10.1200/JCO.2005.05.1003]Search in Google Scholar
[Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.10.1016/S1470-2045(06)70664-7]Search in Google Scholar
[Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-5.10.1182/blood-2010-03-276246295185320548096]Search in Google Scholar
[Horvat M, Jezeršek Novaković B. Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma. Radiol Oncol 2010, 44: 232-8.10.2478/v10019-010-0044-6342370322933921]Search in Google Scholar
[Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.]Search in Google Scholar
[Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-25.10.1182/blood-2010-03-27676620736456]Search in Google Scholar
[Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.10.1038/35000501]Search in Google Scholar
[Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.10.1056/NEJMoa0802885]Search in Google Scholar
[Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-16.10.1016/S1470-2045(08)70002-0]Search in Google Scholar